TY - JOUR
T1 - Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass
T2 - a randomized controlled trial
AU - Waltman, Nancy
AU - Kupzyk, Kevin A.
AU - Flores, Laura E.
AU - Mack, Lynn R.
AU - Lappe, Joan M.
AU - Bilek, Laura D.
N1 - Funding Information:
Research reported in this publication was supported by the National Institute of Nursing Research of the National Institutes of Health under award number R01NR015029.
Funding Information:
Data for this study were collected in a larger study entitled: Bone Loading Exercises versus Risedronate on Bone Health in Post-menopausal women supported by the National Institute of Nursing Research under award number R01NR015029. The study was approved by the Institutional Review Boards at both the University of Nebraska and Creighton University Medical Centers, as both were involved in implementation of the study. Written consent for participation and publication of data were obtained from participants at the time of enrollment. Participants received informed consent documents for review prior to their enrollment visit. Careful and thorough explanations were utilized in obtainment of consent to ensure participant comprehension. The R01 study is registered as a clinical trial under the title: Heartland Osteoporosis Prevention Study (see https://clinicaltrials.gov ).
Publisher Copyright:
© 2021, International Osteoporosis Foundation and National Osteoporosis Foundation.
PY - 2022/2
Y1 - 2022/2
N2 - Purpose: This randomized controlled trial compared changes in bone mineral density (BMD) and bone turnover in postmenopausal women with low bone mass randomized to 12 months of either risedronate, exercise, or a control group. Methods: Two hundred seventy-six women with low bone mass, within 6 years of menopause, were included in analysis. Treatment groups were 12 months of (a) calcium and vitamin D supplements (CaD) (control), (b) risedronate + CaD (risedronate), or (c) bone-loading exercises + CaD (exercise). BMD and serum markers for bone formation (Alkphase B) and resorption (Serum Ntx) were analyzed at baseline, 6, and 12 months. Results: Using hierarchical linear modeling, a group by time interaction was found for BMD at the spine, indicating a greater improvement in the risedronate group compared to exercise (p ≤.010) or control groups (p ≤.001). At 12 months, for women prescribed risedronate, changes in BMD at the spine, hip, and femoral neck from baseline were + 1.9%, + 0.9%, and +.09%; in exercise group women, + 0.2%, + 0.5%, and − 0.4%; and in control group women, − 0.7%, + 0.5%, and − 0.5%. There were also significant differences in reductions in Alkphase B (RvsE, p <.001, RvsC, p <.001) and Serum Ntx (RvsE, p =.004, RvsC, p =.007) in risedronate women compared to exercise and control groups. For risedronate, 12-month changes in Alkphase B and Serum Ntx were − 20.3% and − 19.0%; for exercise, − 6.7% and − 7.0%; and for control, − 6.3% and − 9.0%. Conclusion: Postmenopausal women with low bone mass should obtain adequate calcium and vitamin D and participate in bone-loading exercises. Additional use of BPs will increase BMD, especially at the spine.
AB - Purpose: This randomized controlled trial compared changes in bone mineral density (BMD) and bone turnover in postmenopausal women with low bone mass randomized to 12 months of either risedronate, exercise, or a control group. Methods: Two hundred seventy-six women with low bone mass, within 6 years of menopause, were included in analysis. Treatment groups were 12 months of (a) calcium and vitamin D supplements (CaD) (control), (b) risedronate + CaD (risedronate), or (c) bone-loading exercises + CaD (exercise). BMD and serum markers for bone formation (Alkphase B) and resorption (Serum Ntx) were analyzed at baseline, 6, and 12 months. Results: Using hierarchical linear modeling, a group by time interaction was found for BMD at the spine, indicating a greater improvement in the risedronate group compared to exercise (p ≤.010) or control groups (p ≤.001). At 12 months, for women prescribed risedronate, changes in BMD at the spine, hip, and femoral neck from baseline were + 1.9%, + 0.9%, and +.09%; in exercise group women, + 0.2%, + 0.5%, and − 0.4%; and in control group women, − 0.7%, + 0.5%, and − 0.5%. There were also significant differences in reductions in Alkphase B (RvsE, p <.001, RvsC, p <.001) and Serum Ntx (RvsE, p =.004, RvsC, p =.007) in risedronate women compared to exercise and control groups. For risedronate, 12-month changes in Alkphase B and Serum Ntx were − 20.3% and − 19.0%; for exercise, − 6.7% and − 7.0%; and for control, − 6.3% and − 9.0%. Conclusion: Postmenopausal women with low bone mass should obtain adequate calcium and vitamin D and participate in bone-loading exercises. Additional use of BPs will increase BMD, especially at the spine.
KW - Bone formation and resorption
KW - Bone mineral density (BMD)
KW - Bone-loading exercises
KW - Low bone mass
KW - Postmenopausal women
KW - Risedronate
UR - http://www.scopus.com/inward/record.url?scp=85114894302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114894302&partnerID=8YFLogxK
U2 - 10.1007/s00198-021-06083-2
DO - 10.1007/s00198-021-06083-2
M3 - Article
C2 - 34519832
AN - SCOPUS:85114894302
SN - 0937-941X
VL - 33
SP - 475
EP - 486
JO - Osteoporosis International
JF - Osteoporosis International
IS - 2
ER -